A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder

European Psychiatry

Volumn 12, Issue 2, 1997, Pages 82-93

  Bisserbe, J C ^a   Lane, R M ^b   Flament, M F ^a   Van Moffaert, M ^c   Magerman, J ^c   Ansart, E ^d   Danan, A ^d   Bensoussan, M ^d   Faure, M ^d   Hantz, D ^d   Apse, G ^d   Louboff, F ^d   Guilbert, P ^e   Hantouche, E ^f   Le Goubey, P ^d   Rigaud, M ^d   Lenouene, M C ^d   Moles Durand, M F ^d   Barrere, J ^d   De Mondragon, M ^d   Deroche, D ^d   Leclercq, P ^d   Blauwblomme, J F ^d   Denis, E ^d   Singer, P ^d   Vallee, D ^d   Meynard, J ^g   Wiseman, R ^b   Goldberg, M ^b   Calderon, I ^b   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b PFIZER INC   (United States)

^c Clinique Psychiatrique A (Bat K 13)   (Belgium)

^d Centre Mgen ^*  (France)

^e Centre Mgen   (France)

^f CENTRE HOSPITALIER SAINTE ANNE   (France)

^g CHS Lafond   (France)

Author keywords

Clomipramine; Obsessive compulsive disorder; Sertraline; Y BOCS

Indexed keywords

CLOMIPRAMINE; SERTRALINE;

ADULT; ARTICLE; CLINICAL TRIAL; COMPULSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OBSESSION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREMOR; XEROSTOMIA;

EID: 8044256523     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(97)89646-0     Document Type: Article

References (49)

1. Ananth J, Elmishad A, Wohl M. Clomipramine vs fluoxetine in obsessive-compulsive disorder: an uncontrolled study. Adv Ther Nov-Dec 1993;10:288-92
2. Beaumont G. Sexual side-effects of clomipramine (Anafranil®). J Int Med Res 1973;1:469-72
3. Beaumont G. Sexual side-effects of clomipramine (Anafranil®). J Int Med Res 1977;5(Suppl):37-44
4. Berken GH, Weinstein DO, Stern WC. Weight gain: a side effect of tricyclic antidepressants. J Affective Disord 1984; 7:133-8
5. Chouinard G, Goodman W, Greist J et al. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharm Bull 1990;26:279-84
6. Ciba-Geigy. Review and evaluation of clinical data: Original New Drug Application 19-906 clomipramine (Anafranil). Summit, NJ, 1989
7. The Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:730-8
8. Dickhaut HH, Galiatsos P. Neuartige Wege in der Pharmakotherapie von Verstimmungszuständen mit Anafranil. Nervenarzt 1968;39:552-6
9. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992;160:217-22
10. Flament MF, Rapoport JL, Berg CJ, Sceery W, Kilts C, Mellstrom AB, Linnoila M. Clomipramine treatment of childhood obsessive compulsive disorder. Arch Gen Psychiatry 1985;42:977-83
11. Flament MF, Rapoport JL, Murphy DL, Lake CR, Berg CJ. Biochemical changes during clomipramine treatment of childhood obsessive compulsive disorder. Arch Gen Psychiatry 1987;44:219-25
12. Flament MF, Whitaker A, Rapoport JL et al. Obsessive compulsive disorder in adolescence: An epidemiological study. J Am Acad Child Adolescent Psychiatry 1988;27:764-71
13. Frank E, Kupfer DJ, Bulit CM, Levenson JA. Imipramine and weight gain during the treatment of recurrent depression. J Affective Disord 1993;27:139-45
14. Freeman CP, Trimble MR, Deakin JF, Stokes TM, Ashford JJ. Fluvoxamine versus clomipramine in the treatment of obsessive-compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 1994;55:301-5
15. Goodman WK, Price LH, Delgado PL et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990;47:577-85
16. Greist J, Chouinard G, DuBoff E et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995a;52:289-95
17. Greist J, Jefferson JW, Kobak KA et al. A one year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1995b;10:57-65
18. Greist J, Jefferson JW, Kobak KA et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Arch Gen Psychiatry 1995c;52:53-60
19. Greist JH, Jenike MA, Robinson D, Rasmussen SA. Efficacy of fluvoxamine in obsessive-compulsive disorder: results of a multicentre double-blind, placebo-controlled trial. Eur J Clin Res 1995d;7:195-204
20. Hollander E, McCarley A. Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers. J Clin Psychiatry 1992;53:207-9
21. Jermain DM, Crismon ML. Pharmacotherapy of obsessive-compulsive disorder. Pharmacotherapy 1990;10:175-98
22. Katz RJ, De Veaugh-Geiss T, Landau P. Clomipramine in obsessive-compulsive disorder. Biol Psychiatry 1990;28: 401-14
23. Koran LM, McElroy SL, Davidson JRT, Rasmussen SA, Hollander E, Jenila MA. Double blind comparison of fluvoxamine and clomipramine in obsessive-compulsive disorder in the United States. Eur Neuropsychopharmacology 1995; 5(3):371
24. Kronig MH, Apter J, Asnis G. A multicenter trial of sertraline for obsessive compulsive disorder. Poster presented at the 33rd Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 12-16 December 1994
25. Lopez-Ibor JJ. Ensayo clinico de la monochlorimipramina. (Clinical trial of clomipramine). Proceedings of the IVth World Congress, Madrid, Spain, 1966
26. Marks IM, Stern RS, Dawson B, Cobb J, McDonald R. Clomipramine and exposure for obsessive-compulsive rituals: I. Br J Psychiatry 1980;136:1-25
27. McTavish D, Benfield P. Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive-compulsive disorder. Drugs 1990;39 (Suppl 1):136-53
28. Monteiro WO, Noshirvani HF, Marks IM et al. Anorgasmia from clomipramine in obsessive-compulsive disorder: a controlled trial. Br J Psychiatry 1987;151:107-12
29. Montgomery SA. Clomipramine in obsessional neurosis: a placebo controlled trial. Pharmaceut Med 1980;1:189-92
30. Montgomery SA, McIntyre A, Osterheider M. A double-blind, placebo controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur Neuropsychopharmacology 1993;3:143-52
31. Murdoch D, McTavish D. Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 1992;44:604-24
32. Picinelli M, Pimi S, Ballantuono C, Wilkinson G. Efficacy of drug treatment in obsessive-compulsive disorder. Br J Psychiatry 1995;166:424-43
33. Piggot TA, Pato MT, Bernstein SE, Grover AM, Hill JL, Tolliver TJ, Murphy DL. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results. Arch Gen Psychiatry 1990;47:926-32
34. Preskorn SH, Lane RM. Seitraline 50mg daily - the optimal daily dose in depression. Int Clin Psychopharmacol 1995; 10:129-41
35. Rapoport JL, Ryland DH, Kriete M. Drug treatment of canine acral lick disorder. An animal model of obsessive-compulsive disorder. Arch Gen Psychiatry 1992;49:517-21
36. Rasmussen S, Eisen JL. Clinical and epidemiologic findings of significance to neuropharmacologic trials in OCD. Psychopharm Bull 1988;24:466-70
37. Rasmussen S, Hackett E, Duboff E et al. Long term sertraline in the treatment of obsessive compulsive disorder: a 2-year study. Eur Neuropsychopharmacology 1995;5(3):373
38. Renynghe de Voxrie GV. Anafranil (G 34586) in obsessive neurosis. Acta Neurol Belg 1968;68:787-92
39. Saiz Ruiz J, Lopez Ibor JJ Jr, Cottreaux J et al. Double-blind comparison of fluoxetine and clomipramine in obsessive-compulsive disorder [abstract]. Eur Neuropsychopharmacol Sept 1992;2:204-5
40. Smeraldi E, Erzegovesi S, Bianchi I et al. Fluvoxamine v. clomipramine treatment in obsessive-compulsive disorder: a preliminary study. New Trends Exp Clin Psychiatry 1992;8:63-5
41. Stein DJ, Spadaccini E, Hollander E. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacology 1995;10:11-18
42. Stoll AL, Tohen M, Baidessarini RJ. Increasing frequency of the diagnosis of obsessive-compulsive disorder. Am J Psychiatry 1992;149:638-40
43. Swedo SE, Rapoport JL, Leonard H et al. Obsessive-compulsive disorder in children and adolescents. Arch Gen Psychiatry 1989;46:335-41
44. Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry 1980a;37: 1281-5
45. Thoren P, Asberg M, Bertilsson L, Mellstrom B, Sjogvist F, Traskman L. Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. Arch Gen Psychiatry 1980b;37:1289-94
46. Tollefson GD, Rampey Ir AH, Potvin JH et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994; 51:559-67
47. Weissman MM, Bland RC, Canino GJ et al. The cross national epidemiology of obsessive-compulsive disorder. J Clin Psychiatry 1994;55(Suppl 3):5-10
48. Zohar J, Insel TR. Obsessive-compulsive disorder psychobiological approaches to diagnosis, treatment and pathophysiology. Biol Psychiatry 1987;22:667-87
49. Zohar J, Mueller EA, Insel TR et al. Serotonergic responsivity in obsessive-compulsive disorder: Comparison patients and healthy controls. Arch Gen Psychiatry 1987; 44:946-51